Physician
Kessaris, Dimitri
Kessaris, Dimitri was paid $2.83M by Medicaid between Jan 2018 and Dec 2024, across 74 billing codes. Its largest line is 51728, — 11% of everything it billed.
33Billing provider infoKESSARIS, DIMITRI
MANHASSET, NY 11030
MANHASSET, NY 11030
33aNPI1427022649assigned 02/14/2006
33bProvider typeUrology Physician
28Total paid$2.83M
24GClaims73,318
24DCodes billed74
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Urology Physician providers in New York
Rank by total paid#3 of 461
Median peer was paid$6K
This provider vs. median490×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,758 | $446K | |
| 2019 | 17,355 | $784K | |
| 2020 | 12,891 | $427K | |
| 2021 | 16,003 | $528K | |
| 2022 | 6,862 | $260K | |
| 2023 | 6,640 | $235K | |
| 2024incomplete | 4,809 | $152K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 51728 | 11% | 3,270 | 3,249 | $305K | |
| 88120 | 8.1% | 543 | 538 | $230K | |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.9% | 4,324 | 4,087 | $224K |
| 51792 | 7.5% | 1,522 | 1,506 | $213K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 6.7% | 1,906 | 1,885 | $191K |
| 51784 | 6.5% | 3,741 | 3,607 | $184K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.4% | 4,846 | 4,328 | $181K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 5.0% | 871 | 830 | $140K |
| 76872 | 4.8% | 1,994 | 1,964 | $135K | |
| 52000 | 4.5% | 999 | 998 | $127K | |
| 76857 | 4.1% | 3,523 | 3,491 | $116K | |
| 88112 | 3.6% | 2,348 | 1,984 | $103K |
62 more codes
| 88313 | 3.5% | 2,347 | $100K | |
| 52214 | 3.0% | 237 | $84K | |
| 51741 | 2.6% | 6,514 | $75K | |
| 93976 | 2.4% | 686 | $68K | |
| 53850 | <1% | 33 | $27K | |
| 51798 | <1% | 3,594 | $26K | |
| 51729 | <1% | 155 | $24K | |
| 93922 | <1% | 389 | $24K | |
| 99401 | <1% | 1,080 | $24K | |
| 87556 | <1% | 823 | $18K | |
| 87081 | <1% | 5,152 | $18K | |
| 87640 | <1% | 895 | $15K | |
| 84153 | <1% | 1,511 | $15K | |
| 74178 | <1% | 79 | $13K | |
| 87653 | <1% | 850 | $12K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 823 | $12K |
| 84403 | <1% | 764 | $11K | |
| 81003 | <1% | 7,746 | $11K | |
| 87481 | <1% | 615 | $10K | |
| 76775 | <1% | 525 | $10K | |
| 87563 | <1% | 321 | $8K | |
| 51797 | <1% | 111 | $7K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 32 | $7K |
| 83001 | <1% | 461 | $4K | |
| 83002 | <1% | 462 | $4K | |
| 64566 | <1% | 91 | $4K | |
| 80053 | Comprehensive metabolic panel | <1% | 835 | $4K |
| 77081 | <1% | 203 | $3K | |
| 88342 | <1% | 76 | $3K | |
| 87529 | <1% | 100 | $3K | |
| 87150 | <1% | 17 | $3K | |
| 84146 | <1% | 294 | $3K | |
| 87532 | <1% | 180 | $3K | |
| 88341 | <1% | 76 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 99 | $2K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 48 | $2K |
| 99072 | <1% | 188 | $2K | |
| 76770 | <1% | 42 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 99 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,000 | $2K |
| 99442 | <1% | 61 | $2K | |
| 87511 | <1% | 129 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 99 | $2K |
| 87496 | <1% | 99 | $2K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 259 | $1K |
| 87581 | <1% | 61 | $1K | |
| 95971 | <1% | 74 | $1K | |
| 87541 | <1% | 60 | $998.57 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 18 | $631.48 |
| 76870 | <1% | 12 | $621.67 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 15 | $602.28 |
| 88360 | <1% | 12 | $585.02 | |
| 81002 | <1% | 370 | $550.12 | |
| 87500 | <1% | 30 | $527.68 | |
| 87186 | <1% | 73 | $488.32 | |
| 87498 | <1% | 26 | $472.70 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 263 | $348.22 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 47 | $277.92 |
| 87486 | <1% | 13 | $237.43 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 72 | $72.27 |
| 87088 | <1% | 73 | $46.28 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 12 | $17.74 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.